OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, includin… Read more
OnKure Therapeutics, Inc. (OKUR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.196x
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has a cash flow conversion efficiency ratio of -0.196x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.04 Million) by net assets ($66.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OnKure Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OnKure Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OnKure Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyungji Elite
KO:093240
|
-0.039x |
|
Vortex Consolidated Bhd
KLSE:0060
|
-0.077x |
|
Arianne Phosphate Inc
OTCQX:DRRSF
|
-0.019x |
|
Neo Cremar Co. Ltd
KQ:311390
|
0.024x |
|
Wealth First Portfolio Managers Limited
NSE:WEALTH
|
0.069x |
|
Arribatec Solutions ASA
OL:ARR
|
-0.054x |
|
Peking University Resources (Holdings) Company Limited
F:MKU0
|
N/A |
|
Santierul Naval Orsova SA
RO:SNO
|
0.014x |
Annual Cash Flow Conversion Efficiency for OnKure Therapeutics, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of OnKure Therapeutics, Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $103.83 Million | $-51.12 Million | -0.492x | -245.14% |
| 2023-12-31 | $-101.84 Million | $-34.55 Million | 0.339x | -31.51% |
| 2022-12-31 | $-54.42 Million | $-26.95 Million | 0.495x | +291.96% |
| 2021-12-31 | $147.21 Million | $-37.98 Million | -0.258x | -158.62% |
| 2020-12-31 | $-42.12 Million | $-18.54 Million | 0.440x | -- |